Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

Official title

Vasotoxicity Surveillance Using EndoPAT: The VASA Pilot Study

Overview

This phase I/II trial compares the effect of drugs that causes widening of blood vessels as a result of smooth muscle relaxation (vasodilator therapy) with isosorbide mononitrate, diltiazem or placebo to reduce vasotoxicity in patients with gastrointestinal cancer receiving fluoropyrimidine therapy. Some patients develop chest pain (possibly even a heart attack, a drop in heart function, or a rhythm abnormality) during treatment with a class of cancer drugs known as fluoropyrimidines, which include 5-Fluorouracil (5-FU) and capecitabine. These side effects are believed to be due to the development of an abnormal reactivity of the blood vessels referred to as vasospasm. Vasotoxicity is damage or toxicity inflicted upon blood vessels (vascular system), often causing dysfunction, remodeling, or narrowing (vasoconstriction). It is a broad term used to describe the detrimental effects of certain agents, such as chemotherapy drugs. Researchers want to evaluate how often the reactivity of blood vessels becomes abnormal, during the treatment with 5-FU or capecitabine and how clinically relevant and controllable/preventable this phenomenon is in patients with gastrointestinal cancer.

Interventions

• Procedure Biospecimen Collection
  Undergo blood sample collection
• Drug Capecitabine
  Given IPO
• Drug Diltiazem Hydrochloride
  Given PO
• Procedure Electrocardiogram
  Undergo ECG
• Drug Fluorouracil
  Given IV
• Device Holter Monitoring
  Undergo Holter monitoring
• Drug Isosorbide Mononitrate
  Given PO
• Other Medical Device Usage and Evaluation
  Use EndoPAT
• Drug Placebo Administration
  Given PO
• Other Questionnaire Administration
  Ancillary studies

Primary outcome measures

• Change in reactive hyperemia index (RHI) [Time frame: Baseline (up to 3 days before start of infusion); during infusion; 12-36 hours post-infusion]

Secondary outcome measures (6)

• Proportion of patients with RHI decline ≥ 20% [Time frame: Up to 1 year]
• Proportion of patients with absolute RHI ≤ 2.0 [Time frame: Up to 1 year]
• High-sensitivity troponin T (hsTnT) (indicator of myocardial ischemia) [Time frame: Up to 1 year]
• Presence of Holter abnormalities (ST-segment changes, arrhythmias) [Time frame: Up to 1 year]
• Presence of ischemic symptoms (angina or angina equivalents, dyspnea, claudication) [Time frame: Up to 1 year]
• Seattle Angina Questionnaire (SAQ) [Time frame: Baseline (up to 3 days before start of infusion); during infusion; 12-36 hours post-infusion]

Eligibility criteria

Inclusion criteria

• REGISTRATION: Age ≥ 18 years
• REGISTRATION: Histologically or cytologically confirmed gastrointestinal malignancy (colon, rectal, gastric, esophageal, or other GI cancer) for which fluoropyrimidine therapy (5-FU or capecitabine) is indicated, either as single agent or in combination with other systemic therapy
• REGISTRATION: Planned initiation of 5-FU (infusional) or oral capecitabine therapy, either as standard chemotherapy or as a radiosensitizer
• REGISTRATION: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
• REGISTRATION: Ability to return to Mayo Clinic for baseline and follow-up EndoPAT testing, electrocardiogram (ECG), Holter monitoring, and blood draws
• REGISTRATION: Provide written informed consent
• REGISTRATION: Adequate baseline hemodynamic status: systolic blood pressure ≥ 120 mmHg and resting heart rate ≥ 70 beats/minute (to ensure safety for potential vasodilator therapy in Phase II)
• RANDOMIZATION: Completed all phase I baseline and follow-up assessments, including EndoPAT, ECG, high-sensitivity cardiac troponin T (hs-TnT), and Holter monitoring
• RANDOMIZATION: Demonstrated a ≥ 20% decline in reactive hyperemia index (RHI) from baseline at either phase I follow-up assessment as measured by EndoPAT
• RANDOMIZATION: Adequate hemodynamic status prior to randomization: systolic blood pressure ≥ 120 mmHg and resting heart rate ≥ 70 beats/minute
• RANDOMIZATION: Ability to tolerate and comply with study medication (isosorbide mononitrate, diltiazem, or placebo) per investigator assessment
• RANDOMIZATION: Willingness to initiate study medication 5 days before and continue through the assigned fluoropyrimidine treatment cycle
• RANDOMIZATION: Provide written informed consent for randomization phase

Exclusion criteria

• REGISTRATION: Current or planned treatment with long-acting nitrates or calcium channel blockers at the time of fluoropyrimidine initiation
• REGISTRATION: Known hypersensitivity or contraindication to nitrates or calcium channel blockers
• REGISTRATION: Baseline systolic blood pressure < 120 mmHg or resting heart rate < 70 beats/minute
• REGISTRATION: History of myocardial infarction ≤ 6 months prior to registration, or symptomatic heart failure \[decompensated or New York Heart Association (NYHA) III-IV\] requiring ongoing therapy
• REGISTRATION: Recent acute coronary syndrome or coronary revascularization within 3 months of enrollment
• REGISTRATION: High-grade atrioventricular (AV) block without pacemaker
• REGISTRATION: Use of PDE-5 inhibitors \[e.g. sildenafil (Viagra)\] within 48 hours of enrollment
• REGISTRATION: Uncontrolled intercurrent illness including but not limited to: unstable angina, symptomatic arrhythmias, uncontrolled infection, or psychiatric/social conditions limiting compliance with study requirements
• REGISTRATION: Physical inability to undergo EndoPAT testing (e.g., digital amputation, severe hand deformity, or other limiting condition)
• REGISTRATION: Pregnant or nursing persons
• REGISTRATION: Concurrent enrollment in another interventional clinical trial that, in the opinion of the investigator, would interfere with study endpoints

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Sequential

Masking

Triple blind

Primary purpose

Treatment

Study locations

United States · 1 center

• Mayo Clinic in Rochester — Rochester

Identifiers

NCT: NCT07456852 · MC250411 · NCI-2026-01065 · MC250411 · 25-011528

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗